Results 221 to 230 of about 89,305 (304)

Sialic acids modulate immune responses in cancer: Therapeutic opportunities. [PDF]

J Biol Chem
Bashian EE, Paulson JC, Wu P.
europepmc   +1 more source

Mini‐Catalytically Inactive Cas13X‐Derived RNA Base Editing of β‐Catenin Attenuates Pulmonary Damage in a Murine Acute Lung Injury Model

MedComm, Volume 7, Issue 4, April 2026.
AAV6.2FF‐delivered CARTEL (mini‐dCas13X‐mediated A‐to‐I editor) introduces c.121A>G editing in β‐catenin RNA of alveolar type II cells, leading to sustained Wnt/β‐catenin activation, robust AT2 proliferation, significant attenuation of LPS‐induced acute lung injury, and no excess off‐target edits or fibrotic toxicity for 4 weeks.
Wenyi Liu, Wanda Bi, Saiying Hou, Juan Du, Ling Zeng, Anqiang Zhang, Huacai Zhang, Dalin Wen, Qingli Cai, Chu Gao, Ping Lin, Min Wu, Li Li, Jianxin Jiang   +13 more
wiley   +1 more source

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab‐Atto

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Consistent with previously demonstrated similarity of biosimilar ABP 501 (adalimumab‐atto) with adalimumab reference product, this study in healthy adults demonstrates the pharmacokinetic, safety, and immunogenicity similarity of a high‐concentration formulation (100 mg/mL) of ABP 501 with the original 50mg/mL formulation.
Vincent Chow, Muhan Zhou, Daniel T. Mytych, Alexander Colbert, Mieke Jill Miller, Iwona Wala, Ahad Sabet, Waldemar Radziszewski   +7 more
wiley   +1 more source

Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight‐Based to Flat‐Dosing Strategy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
ABSTRACT Serplulimab is a fully humanized anti–PD‐1 monoclonal antibody approved for small‐cell lung cancer and other malignancies. The initial dosing strategy was based on body weight (WT‐based); however, flat‐dosing offers greater convenience and reduced variability.
Kun Wang, Yuanyuan Shen, Chen Hu, Fengyan Xu, Zhihao Kwok, Qingyu Wang, Yaqi Lin, Yuying Gao, Liang Zhou   +8 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, Volume 117, Issue 4, Page 1093-1105, April 2026.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, Volume 117, Issue 4, Page 917-928, April 2026.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences. [PDF]

Alzheimers Res Ther
Mueller A, Jovalekic A, Chapleau M, Seidel J, Ritter M, Bickel EM, Kiessling N, MacSweeney E, Stephens AW, Koglin N.   +9 more
europepmc   +1 more source

HuAbDiffusion: a discrete language diffusion model used for antibody humanization. [PDF]

Brief Bioinform
Liu D, Hao X, Fan L.
europepmc   +1 more source

OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress. [PDF]

Front Oncol
Yuan Z, Pan Y, Yuan H, Gong A.
europepmc   +1 more source

Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine. [PDF]

Psychopharmacology (Berl)
Berquist MD, Gunnell M, Henry R, Gentry WB, Stevens MW.   +4 more
europepmc   +1 more source